Atlanpole and SATT Ouest Valorisation consolidate their Deeptech plan in Pays de la Loire26 November 2020
Atlanpole, working alongside you to innovate
Valneva Initiates Phase 3 Clinical Lot Consistency Study for its Single-Shot Chikungunya Vaccine Candidate28.01.2021
Valneva Commences Manufacturing of its Inactivated, Adjuvanted COVID-19 Vaccine, Completes Phase 1/2 Study Recruitment12.01.2021
Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
Since the end of 2015, the managers and collaborators of the Atlanpolitan companies have shared their business experiences through seminars and meetings. In this way, they have expanded their networks as well as their skills.